Skip to main content

Advertisement

SpringerLink
Log in

Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations

  • Review Paper
  • Published:
Journal of Pharmacokinetics and Pharmacodynamics Aims and scope Submit manuscript

Abstract

There are many challenges with rare diseases drug development and rare oncology indications are not different. To understand the regulatory landscape as it relates to application of clinical pharmacology principles in rare oncology product development, we reviewed publicly available information of 39 approvals by US FDA between January 2019 and March 2023. The objective was to understand the expected clinical pharmacology studies and knowledge base in such approvals. Model informed drug development (MIDD) applications were also reviewed, as such approaches are expected to play a critical role in filling clinical pharmacology gaps in rare oncology, where number of clinical trials and size of these trials will perhaps continue to be small. The findings highlighted how clinical pharmacology contributed to the evidence of effectiveness, dose optimization and elucidation of intrinsic and extrinsic factors affecting drug’s behavior. Clinical pharmacology studies were often integrated with modeling in many of the NDAs/BLAs. Of the post marketing requirements (PMR) received, 18% were for dose optimization, 49% for DDI, 8% for QTc, 49% for specific population, and 5% for food effect. Two post marketing commitments (PMC) were issued for immunogenicity of the 11 biologics submissions. 15% (6 of 39) of the submissions used maximum tolerated dose (MTD) to advance their molecule into Phase 2 studies. Of them 3 approvals received PMR for dose optimization. 3 + 3 was the most prevalent Phase 1 design with use in 74% of the New Drug Applications (NDA)/Biologic License Applications (BLA) reviewed. Rest used innovative approaches such as BLRM, BOIN or mTPi, with BLRM being the most common. Seamless clinical pharmacology and MIDD approaches are paramount for rare oncology drug development.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. The Orphan Drug Act Implementation and Impact (2001) https://oig.hhs.gov/oei/reports/oei-09-00-00380.pdf. Accessed on 21-August-2023.

  2. National Cancer Institute. https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/about-rare-cancers#:~:text=Rare%20cancers%20are%20those%20that,children’s%20cancers%20are%20considered%20rare. Accessed on 21-August-2023.

  3. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/seerstat/variables/seer/raresiterecode/. Accessed on 21-August-2023

  4. American Cancer Society. Rare Cancers, Cancer Subtypes, and Pre-Cancers. https://www.cancer.org/cancer/types/rare-cancers.html. Accessed on 21-August-2023

  5. Casali PG, Bruzzi P, Bogaerts J J, and, Blay JY (2015) Rare cancers Europe (RCE) methodological recommendations for clinical studies in rare cancers: a European consensus position paper. Ann Oncol 26:300–306

    Article  CAS  PubMed  Google Scholar 

  6. DeSantis CE, Kramer JL, Jemal A (2017) The Burden of Rare cancers in the United States. CA: Cancer J Clin 67:261–272

    PubMed  Google Scholar 

  7. Qosa H, Hassan HE, Younis IR (2022) Overview of clinical Pharmacology packages of New Drug Applications approved for the treatment of Rare Diseases. J Clin Pharmacol 62:S72–S78

    Article  CAS  PubMed  Google Scholar 

  8. Abuasal B, Ahmed MA, Patel P, Albusaysi S, Sabarinath S, Uppoor R, Mehta M (2022) Clinical pharmacology in Drug Development for Rare Diseases in Neurology: contributions and opportunities. Clin Pharmacol Ther 111:786–798

    Article  PubMed  Google Scholar 

  9. New Drugs at FDA: CDER’s New Molecular Entities and New Therapeutic Biological Products. https://www.fda.gov/drugs/development-approval-process-drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products. Accessed on 21-August-2023.

  10. US FDA. Search Orphan Drug Designations and Approvals. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/. Accessed on 21-August-2023

  11. Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/. Accessed on 21-August-2023.

  12. ICH-E4 Guideline for Industry. Dose-Response Information to Support Drug Registration. https://www.fda.gov/media/71279/download. Accessed on 21-August-2023.

  13. Zirkelbach JF, Shah M, Vallejo J, Cheng J, Ayyoub A, Liu J, Hudson R, Sridhara R, Ison G, Amiri-Kordestani L, Tang S, Gwise T, Rahman A, Pazdur R, Theoret MR (2022) Improving dose-optimization processes used in Oncology Drug Development to minimize toxicity and maximize benefit to patients. J Clin Oncol 40:3489–3500

    Article  Google Scholar 

  14. US FDA. Project Optimus. https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus. Accessed on 21-August-2023

  15. US FDA Guidance for Industry. Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases. https://www.fda.gov/media/164555/download. Accessed on 21-August-2023.

  16. US FDA Multi-Discipline Review. Adagrasib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216340Orig1s000MultidisciplineR.pdf. Accessed on 21-August-2023.

  17. US FDA Multi-Discipline Review. Belantamab mafodotin. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761158Orig1s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  18. US FDA Multi-Discipline Review. Futibatinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/214801Orig1s000MultidisciplineR.pdf. Accessed on 21-August-2023.

  19. US FDA Multi-Discipline Review. Infigratinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214622Orig1s000MultidisciplineR.pdf. Accessed on 21-August-2023.

  20. US FDA Multi-Discipline Review. Selinexor. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212306Orig1s000MultidisciplineR.pdf. Accessed on 21-August-2023.

  21. US FDA Multi-Discipline Review. Sotorasib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000MultidisciplineR.pdf. Accessed on 21-August-2023.

  22. US FDA Multi-Discipline Review. Melphalan flufenamide. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000MultidisciplineR.pdf. Accessed on 21-August-2023.

  23. US FDA Multi-Discipline Review. Mirvetuximab. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761310Orig1s000MultidisciplineR.pdf. Accessed on 21-August-2023.

  24. US FDA Multi-Discipline Review. Monsunetuzumab. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761263Orig1s000MultidisciplineR.pdf. Accessed on 21-August-2023.

  25. US FDA Multi-Discipline Review. Tebentafusp. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761228Orig1s000MultidisciplineR.pdf. Accessed on 21-August-2023.

  26. US FDA Multi-Discipline Review. Teclistamab. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761291Orig1s000MultidisciplineR.pdf. Accessed on 21-August-2023.

  27. US FDA Integrated Review. Pacritinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/208712Orig1s000IntegratedR.pdf. Accessed on 21-August-2023.

  28. US FDA Multi-Discipline Review. Lurbinectedin. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213702Orig1s000MultidisciplineR.pdf. Accessed on 21-August-2023.

  29. US FDA Multi-Discipline Review. Fedratinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212327Orig1s000MultidisciplineR.pdf. Accessed on 21-August-2023.

  30. US FDA Multi-Discipline Review. Asciminib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215358Orig1s000,Orig2s000MultidisciplineR.pdf. Accessed on 21-August-2023.

  31. US FDA Multi-Discipline Review. Olutasidenib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/215814Orig1s000MultidisciplineR.pdf. Accessed on 21-August-2023.

  32. US FDA Clinical Pharmacology Review. Ropeginterferon. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/761166Orig1s000ClinPharmR.pdf. Accessed on 21-August-2023.

  33. Poon V, Lu D (2022) Performance of Cox Proportional Hazard models on recovering the Ground Truth of Confounded exposure–response relationships for large-molecule oncology Drugs. CPT Pharmacometrics Syst Pharmacol 11:1511–1526

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Moreau P, Garfall AL, van de Donk NWCJ, Nahi H, San-Miguel JF, Oriol A, Nooka AK, Martin T, Rosinol L, Chari A, Karlin L, Benboubker L, Mateos MV, Bahlis N, Popat R, Besemer B, Martinez-Lopez J, Sidana S, Delforge M, Pei L, Trancucci D, Verona R, Girgis S, Lin SXW, Olyslager Y, Jaffe M, Uhlar C, Stephenson T, Rampelbergh RV, Banerjee A, Goldberg JD, Kobos R, Krishnan A, Usmani SZ (2022) Teclistamab in relapsed or refractory Multiple Myeloma. NEJM 387:495–505

    Article  CAS  PubMed  Google Scholar 

  35. Girgis S, Lin SXW, Pillarisetti K, Verona R, Vieyra D, Casneuf T, Fink D, Miao X, Chen Y, Stephenson T, Banerjee A, Hilder BW, Russell J, Infante J, Elsayed Y, Smit J, Goldberg JD (2023) Effects of Teclistamab and Talquetamab on soluble BCMA levels in patients with Relapsed/Refractory Multiple Myeloma. Blood Adv 7:644–648

    Article  CAS  PubMed  Google Scholar 

  36. US FDA Multi-Discipline Review, Nivolumab, Relatlimab https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/761234Orig1s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  37. US FDA Multi-Discipline Review. Capmatinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213591Orig1s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  38. US FDA Multi-Discipline Review. Tepotinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214096Orig1s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  39. US FDA Multi-Discipline Review. Tazemetostat. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/211723Orig1s000MultidisciplineR.pdf Accessed on 22-August-2023.

  40. US FDA Multi-Discipline Review. Pexidartinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211810Orig1s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  41. US FDA Multi-Discipline Review. Umbralisib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213176Orig1Orig2s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  42. US FDA Multi-Discipline Review. Zanubrutinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/213217Orig1s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  43. US FDA Multi-Discipline Review. Pirtobrutinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/216059Orig1s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  44. US FDA Multi-Discipline Review. Pemigatinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213736Orig1s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  45. US FDA Multi-Discipline Review. Mosunetuzumab. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2023/761263Orig1s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  46. US FDA Multi-Discipline Review. Selumetinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213756Orig1s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  47. Kesisoglou F, Basu S, Belubbi T, Bransford P, Chung J, Dodd S, Dolton M, Heinbach T, Kulkarni P, Lin W, Moir A, Parrott N, Pepin X, Ren X, Sharma P, Stanatopoulos K, Tistaert C, Vaidhyanathan S, Wagner C, Riedmaier AE (2023) Streamlining Food Effect Assessment — Are repeated Food Effect studies needed? An IQ analysis. AAPS J 25:60

    Article  CAS  PubMed  Google Scholar 

  48. Segal EM, Flood MR, Mancini RS, Whiteman RT, Friedt GA, Kramer AR, Hofstetter MA (2014) Oral chemotherapy food and drug interactions: a Comprehensive Review of the literature. J Oncol Pract 10:e255–e268

    Article  PubMed  Google Scholar 

  49. Ji Y, Tan E, Hengelage T, Quinlan M, Hendriks BS (2023) Exploratory Food Effect Assessment in patients in early clinical development of Oncology Drugs. Clin Pharmacol Ther 114:288–302

    Article  CAS  PubMed  Google Scholar 

  50. Riechelmann R, Girardi D (2016) Drug interactions in cancer patients: a hidden risk? J Res Pharm Pract 5(2):77–78

    Article  PubMed  PubMed Central  Google Scholar 

  51. Gatti M, Pea F (2022) The Cytokine Release Syndrome and/or the Proinflammatory cytokines as underlying mechanisms of downregulation of drug metabolism and Drug Transport: a systematic review of the clinical pharmacokinetics of victim Drugs of this drug–Disease Interaction under different clinical conditions. Clin Pharmacokinet 61(11):1519–1544

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Sotorasib Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214665Orig1s000Lbl.pdf

  53. ClinicalTrials.gov. Identifier NCT03028103. https://classic.clinicaltrials.gov/ct2/show/NCT03028103

  54. ICH-E14 Guideline for Industry. Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs. https://www.fda.gov/media/71372/download Accessed on 22-August-2023.

  55. ICH-E14 and S7B Guideline for Industry. Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential — Questions and Answers. https://www.fda.gov/media/161198/download Accessed on 22-August-2023

  56. ICH-S9 Guideline for Industry. Nonclinical Evaluation for Anticancer Pharmaceuticals. https://www.fda.gov/media/73161/download. Accessed on 22-August-2023

  57. Pacritinib Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/208712s000lbl.pdf

  58. ClinicalTrials.gov, Identifier NCT 03037385. https://classic.clinicaltrials.gov/ct2/show/NCT03037385

  59. US FDA Multi-Discipline Review. Pralsetinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213721Orig1s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  60. US FDA Multi-Discipline Review. Mobocertinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  61. Mobocertinib Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215310Orig1s000lbl.pdf

  62. Melphalan Flufenamide Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/214383Orig1s000lbl.pdf

  63. Umbralisib Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/213176Orig1Orig2s000Lbl.pdf

  64. US FDA Multi-Discipline Review. Belzutifan. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2021/215383Orig1s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  65. US FDA Multi-Discipline Review. Avapritinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212608Orig1s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  66. US FDA Multi-Discipline Review. Naxitamab. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/761171Orig1s000MultidisciplineR.pdf. Accessed on 22-August-2023.

  67. US FDA Multi-Discipline Review. Entrectinib. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/212725Orig1s000,%20212726Orig1s000MultidisciplineR.Pdf. Accessed on 22-August-2023.

  68. US FDA Guidance for Industry. Immunigencity Assessment for Therapeutic Protein Products. https://www.fda.gov/media/85017/download. Accessed on 22-August-2023.

  69. Fathallah AM, Oldfield P, Fiedler-Kelly J, Ramadam A (2022) Immunogenicity considerations for therapeutic modalities used in Rare Diseases. J Clin Pharmacol 62:S110–S118

    Article  CAS  PubMed  Google Scholar 

  70. Nathan P et al (2021) Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med 385:1196–1206

    Article  CAS  PubMed  Google Scholar 

  71. Tourneau CL, Lee JJ, Sui LL (2009) Dose escalation methods in Phase I Cancer trials. JNCI 101:708–720

    Article  PubMed  PubMed Central  Google Scholar 

  72. Kurzrock R, Lin CC, Wu TC, Hobbs BP, Pestana RC, Hong DS (2021) Moving beyond 3 + 3. ASCO Educational Book 41:e133–e144

    PubMed  Google Scholar 

  73. Tourneau CL, Gan HK, Razak ARA, Paoletti X (2012) Efficiency of New Dose escalation designs in dose-finding phase I trials of molecularly targeted agents. PLoS ONE 0051039

  74. Yuan Y, Hess KR, Hilsenbeck SG, Gilbert MR (2016) Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials. Clin Cancer Res 22(17):4291–4301

    Article  PubMed  PubMed Central  Google Scholar 

  75. Rasnic R, Linial N, Linial M (2020) Expanding Cancer predisposition genes with Ultra-rare Cancer-Exclusive Human variations. Sci Rep 10:13462

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Boyd N, Dancey JE, Gilks CB, Huntsman DG (2016) Rare cancers: a sea of opportunity. Lancet Oncol 17(2):e52–e61

    Article  PubMed  Google Scholar 

  77. Yang DZ, Alhadab A, Parivar K, Wang DD, Elmeliegy M (2021) Analysis of US Food and Drug Administration Oncology Approvals on the characterization of hepatic impairment effect and dosing recommendations. Clin Pharm Ther 112:782–790

    Article  Google Scholar 

  78. Shah M, Rahman A, Throret MR, Pazdur R (2021) The drug-dosing conundrum in oncology - when less is more. N Engl 385:1445–1447

    Article  Google Scholar 

  79. US FDA Guidance for Industry. Use of Circulating Tumor DNA for Early Stage Solid Tumor Drug Development. https://www.fda.gov/media/158072/download. Accessed on 22-August-2023.

  80. Zou W, Yaung SJ, Fuhlbruck F, Ballinger M, Peters E, Palma JF, Shames DS, Gundara D, Jiang Y, Patil NS (2021) ctDNA predicts overall survival in patients with NSCLC treated with PD-L1 blockade or with chemotherapy. JCO Precis Oncol 5:827–838

    Article  PubMed  Google Scholar 

  81. Cohen SA, Liu MC, Aleshin A (2023) Practical recommendations for using ctDNA in clinical decision making. Nature 619(7969):259–268

    Article  CAS  PubMed  Google Scholar 

  82. Anagnostou V, Ho C, Nicholas G, Juergens RA, Sacher A, Fung AS, Wheatley-Price P, Laurie SA, Levy B, Brahmer JR, Balan A, Niknafs N, Avrutin E, Zhu L, Sausen M, Bradbury PA, O’Donnell-Tormey J, Gaudreau PO, Ding K, Dancey J (2023) ctDNA response after Pembrolizumab in Non-small Cell Lung Cancer: phase 2 adaptive trial results. Nat Med 29:2559–2569

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Barnett H, Boix O, Kontos D, Jaki T (2023) Backfilling cohorts in phase I dose-escalation studies. Clin Trials 20(3):261–268

    Article  PubMed  Google Scholar 

  84. US FDA Model-Informed Drug Development Paired Meeting Program. https://www.fda.gov/drugs/development-resources/model-informed-drug-development-paired-meeting-program Accessed on 22-August-2023.

Download references

Author information

Authors and Affiliations

  1. Clinical Pharmacology, Kura Oncology Inc, Boston, MA, USA

    Amitava Mitra

  2. PK Sciences, Novartis Institutes for BioMedical Research, East Hanover, NJ, USA

    Jong Bong Lee

  3. Clinical Pharmacology and Pharmacometrics, Janssen R&D, Spring House, Titusville, PA, USA

    Douglas Steinbach

  4. Clinical Pharmacology, Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA

    Anasuya Hazra

  5. Drug Development Solutions, Certara USA, Inc, Princeton, NJ, USA

    Rajesh Krishna

Authors
  1. Amitava Mitra
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jong Bong Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Douglas Steinbach
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anasuya Hazra
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rajesh Krishna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amitava Mitra.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mitra, A., Lee, J.B., Steinbach, D. et al. Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations. J Pharmacokinet Pharmacodyn 50, 475–493 (2023). https://doi.org/10.1007/s10928-023-09896-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10928-023-09896-2

Keywords

Search

Navigation